Low 2‐methoxyestradiol levels at the first trimester of pregnancy are associated with the development of pre‐eclampsia

A Pérez‐Sepúlveda, MJ Torres… - Prenatal …, 2012 - Wiley Online Library
A Pérez‐Sepúlveda, MJ Torres, FJ Valenzuela, R Larraín, H Figueroa‐Diesel, J Galaz
Prenatal diagnosis, 2012Wiley Online Library
Objective To determine whether maternal plasma levels of 2‐methoxyestradiol (2‐ME) are
decreased early in pregnancies that subsequently develop pre‐eclampsia (PE) and whether
this difference could be attributed to the presence of Val158Met catechol‐O‐
methyltransferase (COMT) polymorphism in the placenta. Methods Clinical characteristics
and plasma samples were collected at 11 to 14 weeks prospectively in a cohort of patients.
From them, 13 PE and 72 control pregnant women were chosen. Plasma soluble fms‐like …
Objective
To determine whether maternal plasma levels of 2‐methoxyestradiol (2‐ME) are decreased early in pregnancies that subsequently develop pre‐eclampsia (PE) and whether this difference could be attributed to the presence of Val158Met catechol‐O‐methyltransferase (COMT) polymorphism in the placenta.
Methods
Clinical characteristics and plasma samples were collected at 11 to 14 weeks prospectively in a cohort of patients. From them, 13 PE and 72 control pregnant women were chosen. Plasma soluble fms‐like tyrosine kinase1 and placental growth factor levels were measured by electrochemiluminescence and 2‐ME was measured by high‐performance liquid chromatography with mass spectrometry/mass spectrometry detection. At delivery, placental tissue was collected and the Val158Met COMT polymorphism was determined by restriction fragment length polymorphism–PCR.
Results
At 11 to 14 weeks, patients who would develop PE have significantly lower plasma levels of 2‐ME than controls [1.9 ± 2 standard error of the mean (SEM) vs 61.7 ± 27 pg/mL, P < 0.05]. The Val158Met polymorphism was more frequent in controls than in PE patients and the placental presence of COMT polymorphism was associated with a decreased risk of developing PE [PE: 23.1% vs control: 66.6%; χ 2 = 10.9, p = 0.0041].
Conclusions
Lower plasma concentrations of 2‐ME during early pregnancy in patients who subsequently develop PE were found. Presence of placental Val158Met COMT polymorphism is associated with a decreased risk to develop PE, suggesting a protective role against PE. © 2012 John Wiley & Sons, Ltd.
Wiley Online Library